Literature DB >> 30807309

A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.

Steven A Bogen1.   

Abstract

The field of Clinical Immunohistochemistry (IHC) is beset with a high error rate, an order of magnitude higher than in other types of clinical laboratory testing. Despite the many improvements in the field, these errors have persisted over the last 2 decades. The improvements over the years include an extensive literature describing the potential causes of errors and how to avoid them. More stringent regulatory guidelines have also been implemented. These measures reflect the standard view is that fixing the broad confluence of causes of error will address the problem. This review takes a different tack. To understand the high error rates, this review compares Clinical IHC laboratory practice to practices of other clinical laboratory disciplines. What aspects of laboratory testing that minimize errors in other clinical laboratory disciplines are not found in Clinical IHC? In this review, we seek to identify causal factors and underlying root causes that are unique to the field of Clinical IHC in comparison to other laboratory testing disciplines. The most important underlying root cause is the absence of traceable units of measure, international standards, calibrators that are traceable to standards, and quantitative monitoring of controls. These tools and practices (in other clinical laboratory disciplines) provide regular accurate feedback to laboratory personnel on analytic test performance.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/.

Entities:  

Year:  2019        PMID: 30807309      PMCID: PMC6706333          DOI: 10.1097/PAI.0000000000000750

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  63 in total

Review 1.  Errors in laboratory medicine.

Authors:  Pierangelo Bonini; Mario Plebani; Ferruccio Ceriotti; Francesca Rubboli
Journal:  Clin Chem       Date:  2002-05       Impact factor: 8.327

2.  Synthetic peptides identified from phage-displayed combinatorial libraries as immunodiagnostic assay surrogate quality-control targets.

Authors:  Seshi R Sompuram; Vani Kodela; Halasya Ramanathan; Charles Wescott; Gail Radcliffe; Steven A Bogen
Journal:  Clin Chem       Date:  2002-03       Impact factor: 8.327

3.  HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Authors:  Edith A Perez; Vera J Suman; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Wilma L Lingle; Patrick J Flynn; James N Ingle; Daniel Visscher; Robert B Jenkins
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

Review 4.  Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It.

Authors:  Allen M Gown
Journal:  Arch Pathol Lab Med       Date:  2016-09       Impact factor: 5.534

5.  A model for a comprehensive measurement system in clinical chemistry.

Authors:  N W Tietz
Journal:  Clin Chem       Date:  1979-06       Impact factor: 8.327

6.  Levey-Jennings Analysis Uncovers Unsuspected Causes of Immunohistochemistry Stain Variability.

Authors:  Kodela Vani; Seshi R Sompuram; Stephen P Naber; Jeffrey D Goldsmith; Regan Fulton; Steven A Bogen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016 Nov/Dec

7.  Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

Authors:  Ann E McCullough; Patrizia Dell'orto; Monica M Reinholz; Richard D Gelber; Amylou C Dueck; Leila Russo; Robert B Jenkins; Stefania Andrighetto; Beiyun Chen; Christian Jackisch; Michael Untch; Edith A Perez; Martine J Piccart-Gebhart; Giuseppe Viale
Journal:  Breast Cancer Res Treat       Date:  2014-01-07       Impact factor: 4.872

8.  Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer.

Authors:  Yan Xiao; Xiugong Gao; Samantha Maragh; William G Telford; Alessandro Tona
Journal:  Clin Chem       Date:  2009-05-14       Impact factor: 8.327

9.  Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study.

Authors:  Tülay Canda; Ekrem Yavuz; Necmettin Özdemir; Sennur İlvan; Serpil Sak Dizbay; Merih Güray Durak; Sıtkı Tuzlalı; Osman Zekioğlu; Atakan Demir; Handan Onur; Kasım Üstündağ; Burçe Göktaş
Journal:  Eur J Breast Health       Date:  2018-07-01

10.  HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.

Authors:  Dan Huang; Ning Lu; Qinhe Fan; Weiqi Sheng; Hong Bu; Xiaolong Jin; Guimei Li; Yanhui Liu; Xianghong Li; Wenyong Sun; Huizhong Zhang; Xiaobing Li; Zongguang Zhou; Min Yan; Xuan Wang; Weihong Sha; Jiafu Ji; Xiangdong Cheng; Zhiwei Zhou; Jianming Xu; Xiang Du
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

View more
  4 in total

1.  Development and Validation of Measurement Traceability for In Situ Immunoassays.

Authors:  Emina E Torlakovic; Seshi R Sompuram; Kodela Vani; Lili Wang; Anika K Schaedle; Paul C DeRose; Steven A Bogen
Journal:  Clin Chem       Date:  2021-04-29       Impact factor: 8.327

Review 2.  Recent advances in nanomaterials-based electrochemical immunosensors and aptasensors for HER2 assessment in breast cancer.

Authors:  Rajesh Ahirwar
Journal:  Mikrochim Acta       Date:  2021-09-02       Impact factor: 5.833

3.  Digital Image Analysis and Quantitative Bead Standards in Root Cause Analysis of Immunohistochemical Staining Variability: A Real-world Example.

Authors:  Rebecca Rojansky; Seshi R Sompuram; Ellen Gomulia; Yasodha Natkunam; Megan L Troxell; Sebastian Fernandez-Pol
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-07-13

4.  Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934.

Authors:  Seshi R Sompuram; Emina E Torlakovic; Nils A 't Hart; Kodela Vani; Steven A Bogen
Journal:  Mod Pathol       Date:  2021-08-13       Impact factor: 7.842

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.